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Objectives: To compare Cystic Fibrosis (CF) severity with NOS-1 polymorphisms
(pol.) (AAT, TG1 and TG2) and CFTR interaction.
Methods: 181 patients included. The NOS-1 pol. was analyzed by Megabace1000®
sequencer. Variables: sex, race, scores [Shwachman-Kulczycki, Kanga and Bhalla
(EB)], BMI, age, diagnosis age, ﬁrst symptoms (digestive and pulmonary), ﬁrst
P. aeruginosa, microorganisms (P. aeruginosa mucoid and non-mucoid, A. xylos-
oxidans, S. aureus, B. cepacia), SaO2, spirometry and comorbidities (nasal polyps,
osteoporosis, meconium ileus, pancreatic insufﬁciency, diabetes mellitus). Statis-
tical analysis: MDR2.0 and MDRPT0.4.7 software. Numerical data: classiﬁed by
the median. Categorical data: presence or absence (bacteria and comorbidities).
Multiple genes analysis in disease with clinical variation, like CF, allows greater
understanding of phenotypic diversity. The analysis of all alleles for NOS-1 and
CFTR did not show association. The same was observed to alleles with more
repetitions in NOS-1. However, alleles with minor repetitions in NOS-1 and CFTR
showed association with the race and age. For race, the ratio between Caucasian and
non-Caucasian was not similar and the p-value becomes irrelevant. Regarding age,
only the CFTR was associated. Finally, there was association of minor repetitions to
the TG1 and TG2 pol. in NOS-1, along with CFTR, with BS (measures the degree of
impairment of structure bronchopulmonary) (Ratio: 0.954; Ball Test. Acc: 0.643,
p: 0.033). The BS is a marker of early lung disease and is associated with the
clinical severity, being considered an important factor in clinical prediction.
Conclusion: NOS-1 and CFTR interaction inﬂuence BS value in CF.
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The most frequent CF-causing mutation − F508del − prevents cell surface expres-
sion of CFTR because it is retained in the endoplasmic reticulum (ER) by the ER
quality control which prematurely targets it for ER-associated degradation due to
its misfolded conformation.
Objectives: To identify genes that modulate trafﬁc of wt-CFTR and/or rescue
F508del-CFTR to the cell surface as novel therapeutic targets for CF.
Methods: A549 alveolar epithelial cells stably transfected with a mCherry-CFTR
construct encompassing an extracellular Flag-tag were used to perform and validate
a high content screen of a druggable genome siRNA library (Ambion) [1]. The
ﬂuorescence ratio of immunodetected Flag versus mCherry quantiﬁed the fraction
of CFTR in the plasma membrane under each knock down condition and thus the
trafﬁcking efﬁciency.
Results and Conclusion: Screening one third of the siRNA library revealed
178 siRNAs enhancing and 126 siRNAs inhibiting wt-CFTR trafﬁc efﬁciency
(over two SEM values from controls). A secondary (validation) screen conﬁrmed
hits including G protein-coupled receptors, chaperones and proteins involved in
sterol binding, beta-catenin signaling, nuclear/chromatin structuring, cytoskeletal
dynamics, cell differentiation and channel regulation. Further research will focus
on identifying therapeutically relevant genes involved in F508del-CFTR retention.
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